Skip to main content

PerkinElmer Q2 Profit Declines 15 Percent on 2.5-Percent Revenue Growth

This article has been updated to correct the change in PerkinElmer's net income, which declined to $24.5 million, not by $24.5 million.

NEW YORK (GenomeWeb News) – PerkinElmer today said second-quarter net income declined 15 percent as revenues inched up 2.5 percent.
 
Receipts for the three months ended July 2 increased to $377 million from $368 million year over year.
 
Revenue from the Life and Analytical Sciences segment increased 3 percent to $278.5 million from $270.8 million year over year. The genetic screening and service businesses contributed to the increase, the company said in a statement.
 
Revenue for the Optoelectronics segment remained essentially flat, at $98.5 million compared to $97 million from the same period last year.
 
R&D costs increased 13 percent to $25 million from $22 million from the comparable quarter a year ago.
 
PerkinElmer also reported a decline in net income to $24.5 million for the second quarter compared to $29 million last year.
 
PerkinElmer had $324 million in cash and cash equivalents as of July 2.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.